Are more patients with obesity opting for GLP-1 drugs over other weight-loss options, including lifestyle changes or bariatric procedures
Do not discontinue the medication without consulting your healthcare provider, even if you feel better
The regulator continues to process generic applications under its 180-day review timeline, with first approvals potentially coming as early as this summer
Patient safety guidance should include: Education about expected appetite changes and strategies for maintaining adequate nutrition Monitoring for excessive weight loss or signs of malnutrition Assessment of mental health at follow-up visits Clear instructions to report severe or persistent nausea, vomiting, or neuropsychiatric symptoms Awareness that cognitive effects remain investigational and should not influence prescribing decisions Reporting severe persistent abdominal pain (pancreatitis), right upper quadrant pain/jaundice (gallbladder disease), severe abdominal distension with inability to pass gas or stool (possible ileus), persistent vomiting or signs of dehydration, and new/worsening vision changes (retinopathy) Understanding increased hypoglycemia risk when combined with insulin or sulfonylureas GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with severe gastrointestinal disease, including gastroparesis
Sudden weight reduction or maladaptation to an altered body perception may elicit biological and psychological reactions that can potentially impact suicidal thoughts
Scott Butsch, director de medicina para la obesidad en la Clnica Cleveland
.png.jpg)
